About 40% of the world population present serological evidence of present or past infection by hepatitis B virus (HBV), corresponding to around 300-350 million HBV carriers worldwide ([@B8]). Recently, the Ministry of Health of Brazil conducted a national survey in the country's capitals to assess the prevalence of viral hepatitis, Brazil being considered an area of low endemicity for hepatitis B, with hepatitis B surface antigen (HBsAg) prevalence from 0.40-0.92% in different regions ([@B20]), although some areas are considered to be highly endemic ([@B29]). Thus, chronic hepatitis by HBV is still considered a public health issue, resulting in expressive morbidity and mortality rates around the world.

Two drug classes are available for the treatment of chronic infections by HBV: nucleos(t)ide analogues, which directly inhibit HBV-DNA replication, and interferon (IFN) alpha-based drugs, which can modulate the host response as well as viral replication. Nucleoside analogues \[lamivudine (LAM), telbivudine, and entecavir (ETV)\] and nucleotides \[adefovir and tenofovir (TDF)\] are currently available, as well as IFN-based drugs: conventional IFN (alpha 2a and 2b) and pegylated IFN (alpha 2a and 2b) ([@B6]).

While international consensus establishes nucleos(t)ide analogues of high genetic barrier as firs-rate drugs in the treatment of HBV, the Brazilian public health system ([@B19]) prioritises TDF over ETV, probably for economic reasons.

There are no real-life studies in Brazil assessing the long-term response to nucleos(t)ide analogues as well as the occurrence of adverse events and the emergence of resistance in the treatment of patients with chronic hepatitis by HBV. Therefore, the evaluation of treatment response can pose practical applications for the population of patients treated in the public health system in Brazil.

The objective of the present study is to assess the effectiveness of the nucleos(t)ide analogues available through the public health system in Brazil (ETV and TDF) for the treatment of chronic hepatitis by HBV.

PATIENTS, MATERIALS AND METHODS
===============================

This is a cross-sectional study conducted by reviewing medical records during the period from March-December 2013. All patients with chronic hepatitis B undergoing treatment through the public health system in southern Brazil, over 18 years of age, and presenting data for at least one reassessment of treatment in their medical records according to the rules established by the Brazilian public health system ([@B19]) were included.

Only data relating to the first treatment carried out with ETV or TDF in patients who had received no prior therapy was considered.

Patients who had undergone solid organ transplantation, co-infected with hepatitis C virus (HCV) and/or the human immunodeficiency virus (HIV), and subjected to immunosuppression for any reason were excluded from the study.

Available record data related to demographics (age, gender, ethnicity) and liver biopsy classified according to METAVIR score ([@B1]), as well as the type of nucleos(t)ide analogue used, usage time, and response to treatment were recorded. The assessment of response to treatment was performed using available data relating to viral load (VL) (quantitative HBV-DNA), hepatitis B e antigen (HBeAg), antibody to the e antigen (anti-HBe), HBsAg, antibody to the surface antigen (anti-HBs), and alanine aminotransferase (ALT) pre-treatment, at six months, at one year, and at the end of the monitoring period. The end of monitoring was defined as the last evaluation registered in the medical records for those patients who were under treatment for more than one year.

The response to the treatment was established by the occurrence of viral suppression, which was defined by the negativation of the VL.

The outcomes assessed in HBeAg-positive patients were ALT normalisation, HBeAg negativation, seroconversion to anti-HBe, negativation or reduction of HBV-DNA below the detection value, and HBsAg negativation with or without seroconversion to anti-HBs ([@B6]).

For the HBeAg negative and anti-HBe positive (pre-core/core-promoter mutation) patients, the outcomes were ALT normalisation, HBV-DNA negativation or reduction below the detection value, and HBsAg negativation with or without seroconversion to anti-HBs ([@B6]).

The emergence of virologic resistance was established when there was an increase of HBV-DNA (\> 1 log) in the patients undergoing treatment after achieving virological response with previous HBV-DNA negativation ([@B6]).

Assessment of renal function during treatment was performed evaluating serum creatinine.

Biochemical tests were performed in accordance with the recommendation of the Brazilian protocol ([@B19]). The HBsAg, HBeAg, and anti-HBe tests were performed using commercial radioimmunoassay tests in accordance with the manufacturer's instructions. Quantitation of HBV-DNA was performed by polymerase chain reaction (PCR) ([@B27]), provided by the central public health laboratory.

The statistical package SPSS v.22.0 was used for the analysis of the results. Quantitative variables were presented as mean and standard deviation or mean and interquartile range when they were not normally distributed. For mean comparisons we used the Mann-Whitney *U* test. The qualitative variables were presented in the form of frequency and percentage. To check the associations between these variables, we used Pearson's chi-square test with the additional feature of the adjusted residuals analysis to identify the location of the associations. The significance level was 5%. Regarding the calculated p-value, this was represented as \< 0.001.

The data was obtained through the chart review in the public domain. The research project was approved by the Ethical Committee of the Federal University of Health Sciences of Porto Alegre (protocol 332-486/2013). The study followed the regulatory guidelines and standards for human research according to the resolution 466/2012 of the National Health Council.

RESULTS
=======

Six hundred and forty-eight patients were assessed. Of these, eight were excluded (2 for HIV co-infection, 2 for HCV co-infection, and 4 transplant recipients), totalling 640 patients. Regarding the choice of medication, TDF was used in 336 (52.5%) patients and ETV in 165 (25.8%) patients. Of the remaining patients, 61 (9.5%) used LAM and 78 (12.2) used various combinations of nucleos(t)ide analogues, being excluded from the present analysis.

Patients treated with ETV were significantly older than those treated with TDF. Caucasians represented more than 90% of patients in both treatments. Men were the majority, representing 80.5% in those treated with ETV and 64.6% in those treated with TDF (p \< 0.001). The mean pre-treatment VL of patients using ETV was approximately three times higher than that of patients using TDF (p = 0.005). No statistically significant difference was found in the pre-treatment ALT values between patients with ETV/TDF.

Among the 165 patients treated with ETV, 135 underwent testing for HBeAg and, of these, 24 (17.8%) were HBeAg-positive, while of the 336 patients treated with TDF, 303 underwent testing for HBeAg, and of these, 25 (8.2%) were HBeAg-positive (p = 0.006). There were more cirrhotic patients treated with ETV than with TDF: six (13.6%) and two (2.2%), respectively ([Table I](#t1){ref-type="table"}).

TABLE IPre-treatment baseline characteristics of patientsVariableEntecavir (n = 165)Tenofovir (n = 336)pAge (years) \[mean (SD)\]55.8 (12.1)47.7(11.2)\< 0.001Caucasian \[n (%)\]157 (96.3)312 (93.4)0.220Male gender \[n (%)\]133 (80.5)217 (64.6)\< 0.001Viral load (IU/mL) mean (p25, p75)^*a*^82,850 (1,670; 5,584,400)27,998 (5,240; 1,001,600)0.005Initial ALT (U/L) mean (p25; p75)^*a*^47 (27; 106)39 (22; 79)0.230HBeAg positive \[n (%)\]24 (17.8)25 (8.2)0.006Cirrhosis \[n (%)\]6 (13.6)2 (2.2)0.016[^1]

All patients were under treatment during the whole period of evaluation. However, the number of patients evaluated in each period was not the same. From the total of patients, there were 254 patients evaluated at the 6th month of treatment, 294 evaluated at the end of the first year of treatment, and 162 evaluated at the end of the monitoring period. Patients who used ETV had been undergoing treatment for longer than those using TDF. Treatment time with ETV varied between 3.1-43.6 months (25% treated for a period of 12.2 months, 50% for 18.3 months, and 75% for 25.4 months). With regard to TDF, the treatment time varied between 3.1-42.6 months (25% treated for a period of 10.1 months, 50% for 16.3 months, and 75% for 22.3 months) (p = 0.015).

The number of patients with undetectable VL in the three monitoring periods was similar between the two medications ([Table II](#t2){ref-type="table"}). At the end of six months, the percentage difference in patients with undetectable VL between the medications was only 0.7% (p = 0.912). After one year of treatment, this difference reached 1% (p = 0.803) and at the end of the monitoring period the difference between medications was 8.5% (p = 0.126).

TABLE IIAnalysis of viral load (VL) according to the treatment periodAssessment period6 months1 yearEnd of monitoring \> than 1 yearpUndetectable VL \[n/n (%)\]ETV58/92 (63)91/105 (86.7)55/63 (87.3)\< 0.001TDF101/162 (62.3)162/189 (85.7)78/99 (78.8)\< 0.001VL (IU/mL)ETV601,131 (n = 92)3,800 (n = 105)499 (n = 63)0.001TDF722,873 (n = 162)43,591 (n = 189)2,458 (n = 99)0.001[^2]

It was observed that the VL prior to treatment was negative in 10.1% of patients using ETV and 2.8% in the group of patients using TDF. Throughout the treatment, there was a progressive increase in the number of patients with negative VL, reaching 87.3% and 78.8% at the end of monitoring for ETV and TDF, respectively, which was statistically significant for both treatments (p \< 0.001). There was also a progressive decrease in median VL in both treatments during the follow-up period. The data related to the VL can be seen in [Table II](#t2){ref-type="table"}.

The development of resistance was observed in three patients (3.03%) using TDF and in one (1.59%) using ETV (p \> 0.05).

Regarding HBeAg negativation, it was observed that in the pre-treatment period there were 24 (17.8) and 25 (8.2%) HBeAg-positive patients treated with ETV and TDF, respectively. At the end of the monitoring period there were five (3.9%) HBeAg-positive patients in the ETV group and seven (2.5%) in the TDF group (p = 0.508). Among patients who became HBeAg-negative, only three (1.8%) who used ETV and one (0.03%) who used TDF presented seroconversion to anti-HBe.

There were no cases of HBsAg negativation during the assessed period.

The different outcomes according to the medication used can be observed in [Table III](#t3){ref-type="table"}.

TABLE IIIDifferent outcomes according to the medication usedETV \[n/n (%)\]TDF \[n/n (%)\]pHBV-DNA loss146/165 (88.5)240/288 (83.3)0.376HBeAg loss19/24 (79)18/25 (72)0.508Anti-HBe seroconvertion3/19 (15.8)1/18 (5.56)0.604ALT normalisation36/72 (50)68/128 (53.1)0.671[^3]

Among the 79 patients with elevated ALT treated with ETV, normalisation was observed in 45 (59.5%) and, among the 133 patients with elevated ALT treated with TDF, 67 (50.4%) presented normalisation (p = 0.198).

There were no records of liver decompensation in cirrhotic patients or the emergence of hepatocellular carcinoma (HCC) during the monitoring period. Likewise, there were no records of the occurrence of adverse effects such as loss of renal function.

DISCUSSION
==========

The goal of antiviral therapy in chronic hepatitis B patients is the suppression of HBV-DNA, the negativation of HBeAg, its seroconversion, and, at last, to obtain the negativation of HBsAg with seroconversion to anti-HBs. Secondary outcomes are also expected, such as the decrease in mortality ([@B6], [@B12]). It has been reported that long-term treatment with nucleos(t)ide analogues can slow - and even reverse - the progression of fibrosis ([@B12], [@B33]).

The majority of studies conducted in real-life with treatment-naïve patients receiving ETV or TDF were performed in Europe or in Asia ([@B21], [@B8], [@B14]). To our knowledge, there is only one study conducted in South America that assessed treatment-naïve patients treated with ETV in real-life ([@B26] and there are no studies assessing the use of TDF or comparing two analogues in HBV patients.

In the present study, it was possible to demonstrate that treatment with ETV and TDF is safe and effective, with VL negativation occurring in the majority of patients with both medications (87.3% and 78.8%, respectively). Likewise, HBeAg negativation was achieved in the majority of cases - in 79% (19/24) of those treated with ETV and in 72% (18/25) of those treated with TDF. However, seroconversion to anti-HBe was obtained in a small number of patients and there was no negativation of HBsAg. The development of viral resistance occurred in a small number of cases in patients using ETV and TDF (1.59% and 3.03%, respectively).

Although the assessed population had a higher mean age in the group of patients using ETV than in the group using TDF (55.8 and 47.7 years), as well as a higher male gender presence, there was no significant difference regarding ethnicity. This is comparable to the literature, where real-life studies included patients treated with ETV with a mean age between 36-58 years ([@B12], [@B28], [@B33], [@B2], [@B5], [@B26],[@B31] and patients treated with TDF were between 36-55 years of age ([@B11], [@B22], as well as a male gender majority in those treated with ETV, between 59-85% of cases ([@B4], [@B10], [@B18], [@B36],[@B3], [@B21], [@B32], [@B7],[@B13], [@B15], [@B16], [@B34], [@B26], as well as TDF, between 50-74% ([@B18], [@B13]. With regard to ethnicity, some authors included, in their studies, Asian patients who used ETV ([@B4], [@B10], [@B21], [@B32], [@B16] or TDF ([@B9].

The mean treatment time in the present study was similar to other studies ([@B10], [@B21], [@B31]), thus being sufficient to establish the effectiveness and safety of the treatments employed.

The VL negativation was achieved in 87.3% and 78.8% of patients who received ETV and TDF, respectively, at the end of the monitoring period. It has been described that the response to nucleos(t)ide analogues with VL negativation can reach more than 90% in one-two years of treatment ([@B6]). In real-life, studies have shown VL negativation rates ranging between 44-100% in those treated with ETV ([@B36],[@B3], [@B21], [@B32], [@B7],[@B13], [@B15], [@B16], [@B34], [@B26]) and between 76-97% in those treated with TDF ([@B13]).

HBeAg negativation was observed in 79% and 72% for ETV and TDF, respectively. According to the literature review, these values vary from 0-99% for ETV ([@B4], [@B10], [@B36], [@B3], [@B21], [@B32], [@B7], [@B13],[@B15], [@B16], [@B34], [@B25]) and from 0-100% for TDF ([@B18], [@B13]).

In the present study, no cases of HBsAg negativation or seroconversion to anti-HBs were observed. Similar data was also observed in other studies ([@B15]), presenting low rates, or absence of HBsAg negativation and HBsAg seroconversion. In a recent systematic review ([@B30]), HBsAg negativation occurred in 0-14% for ETV and 0-13% for TDF.

Patients with advanced liver disease have some risk of decompensation during treatment ([@B24], [@B25]) and some authors ([@B23], [@B35]) report the development of HCC after HBV treatment, showing that even with viral suppression, patients should be monitored for this complication. There were no records of hepatic decompensation or the emergence of HCC during the monitoring period in the present study.

[@B25] carried out a recently published systematic review in which Phase III studies were included for hepatitis B treatment, with studies using ETV ([@B4], [@B10], [@B36], [@B3], [@B21], [@B32], [@B7], [@B13], [@B15], [@B16], [@B34], [@B26]) or TDF ([@B18], [@B13]). The average monitoring time varied between 12-58 months, totalling 4,681 patients. The HBV-DNA negativation occurred in 44-100%, HBeAg seroconversion in 8-68%, and HBsAg negativation in 0.2-14%. The average monitoring time varied from 12-33 months, totalling 574 patients, with HBV-DNA negativation in 76-97%, HBeAg seroconversion in 5-36%, and HBsAg negativation in 0-13%.

As observed in the present study, there were no significant differences between the two treatments (ETV or TDF).

[@B22] carried out comparisons between patients treated with TDF (121 patients) and ETV (130 patients). Participants were selected from 10 care centres and the average treatment time was 17.7 ± 10.3 months. Patients showed comparable rates of HBV-DNA negativation (66.7% and 74.3%), HBeAg negativation (9.2% and 34.6%), and anti-HBe development (22.7% and 25.9%), respectively. Both medications provided effective viral control, with few side effects.

[@B9] recently published a systematic review and meta-analysis including seven studies that compared ETV and TDF. Despite the small sample sizes in the analysed studies, there were no differences between the two medications \[relative risk (RR) 1.10, 95% confidence interval (CI) 0.91-1.33 and RR 1.07, 95% CI 0.99-1.17 for 24 and 48 weeks of treatment, respectively), concluding that TDF and ETV are similar in effectiveness and safety at 24 and 48 weeks of treatment.

In general, studies observed a low incidence of resistance and viral escape (below 1% for ETV and TDF), with low levels of side effects and low incidence of discontinuation due to drug intolerance ([@B17], [@B9], [@B22]). In this study, the development of resistance was observed in four patients. However, it is not possible to define the influencing factors for such occurrences, since the irregular supply of the medications or nonadherence to treatment may be involved, factors that were not measured in this study.

TDF presents renal excretion with reports of renal function alterations in the literature ([@B9]). On the other hand, ETV presents a risk of lactic acidosis development in patients with decompensated cirrhosis ([@B28]). In the present study, there were no records of the occurrence of side effects potentially related to the use of these drugs. However, we understand that this data might be underestimated, as this is a retrospective study.

In conclusion, the present study differed from randomised clinical trials, being a study in real-life conditions and that adds information about long-term treatment effectiveness as well as safety in clinical practice. It was shown that both medications (ETV and TDF) have a high rate of HBV VL negativation and an excellent safety profile.

[^1]: *a*: p25 and p75 represent the first and third quartiles, respectively; ALT: alanine aminotransferase; HbeAg: hepatitis B e antigen; IU: international units; SD: standard deviation.

[^2]: ETV: entecavir; IU: international units; TDF: tenofovir.

[^3]: ALT: alanine aminotransferase; anti-HBe: antibody to the e antigen; ETV: entecavir; HBeAg: hepatitis B e antigen; HBV: hepatitis B virus; TDF: tenofovir.
